Multiple Sclerosis Drugs - Ukraine

Ukraine

Highlights

The revenue generated in the Multiple Sclerosis Drugs market in Ukraine is projected to reach US$11.15m in 2024.
It is expected to show an annual growth rate of 1.34% from 2024 to 2029, resulting in a market volume of US$11.91m by 2029.
In global comparison, United States is expected to generate the highest revenue of US$11.77bn in 2024.
The demand for Multiple Sclerosis drugs in Ukraine is steadily increasing due to a growing awareness and better access to healthcare services.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Multiple Sclerosis Drugs market in Ukraine has been experiencing a steady growth in recent years.

Customer preferences: Patients in Ukraine suffering from Multiple Sclerosis have shown a preference for disease-modifying therapies (DMTs) that can slow down the progression of the disease. The preference for DMTs is due to the fact that the disease is chronic and has a significant impact on the quality of life of patients.

Trends in the market: One of the major trends in the Multiple Sclerosis Drugs market in Ukraine is the increasing availability of biosimilars. Biosimilars are cheaper versions of biologic drugs that have already been approved by regulatory authorities. The availability of biosimilars has increased competition in the market, leading to lower prices and increased access to treatment for patients.Another trend in the market is the increasing use of oral therapies. Oral therapies are more convenient for patients compared to injectable therapies. This trend is driven by the availability of new oral therapies that have been approved for the treatment of Multiple Sclerosis in recent years.

Local special circumstances: One of the challenges in the Multiple Sclerosis Drugs market in Ukraine is the low level of healthcare spending. This has resulted in limited access to treatment for patients, particularly those living in rural areas. Additionally, the reimbursement system for drugs in Ukraine is complex, which has led to delays in patients receiving treatment.

Underlying macroeconomic factors: The Ukrainian economy has been growing in recent years, which has led to an increase in healthcare spending. However, the level of healthcare spending in Ukraine is still relatively low compared to other European countries. The government has implemented reforms aimed at improving the healthcare system, which is expected to lead to increased access to treatment for patients in the future.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.